The FDA approved lirafugratinib in FGFR2+ cholangiocarcinoma and belzutifan plus lenvatinib in advanced ccRCC, and more.
|Videos|December 26, 2017
Dr. Voss on the Future of Clinical Trials for Kidney Cancer
Author(s)Martin H. Voss, MD
Martin H. Voss, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the future of the clinical trial space for patients with kidney cancer.
Advertisement
Martin H. Voss, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the future of the clinical trial space for patients with kidney cancer.
According to Voss, collaboration is important for the neoadjuvant concepts that are being developed. It is important discuss systemic therapies in a surgical context and as a multidisciplinary effort.
The key to successful development of approaches is to have a multidisciplinary team involved, says Voss.
Advertisement
Related to this article
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The FDA has approved belzutifan (Welireg) plus lenvatinib (Lenvima) for use in patients with advanced renal cell carcinoma with a clear cell component after PD-1 or PD-L1 inhibition.
Advertisement
Advertisement
Trending on OncLive
1
Ifinatamab Deruxtecan BLA Voluntarily Withdrawn in Previously Treated Extensive-Stage SCLC
2
FDA Grants Priority Review to Perioperative Durvalumab Plus Neoadjuvant Enfortumab Vedotin in MIBC
3
FDA Approves Belzutifan Plus Lenvatinib for Advanced ccRCC
4
Long-Term PERSEUS Data Confirm Durable PFS Benefit With D-VRd in Transplant-Eligible Newly Diagnosed Myeloma
5